PROJECT SUMMARY
Timely and accurate diagnosis of ocular infections is critical to support early effective therapy and save vision.
Serious infections such as infectious keratitis, uveitis and endophthalmitis are leading causes of blindness
globally. These infections are caused by a wide range of pathogens, which can often present with overlapping
features and are difficult to differentiate clinically. Laboratory-based diagnosis is an important component of
clinical management to guide efficient deployment of therapies. However, because current methods employed
for pathogen detection are outdated, time-consuming and lack sensitivity, patients can be treated for prolonged
periods with combinations of empirical broad-spectrum therapies that are not tailored for an individual, may be
ineffective, cause needless ocular toxicity, and are becoming compromised by the emergence of antimicrobial
resistance. Rapid precision diagnostic tests are critically needed to help guide therapy and improve patient
outcomes. To address this critical and urgent need, we are developing novel and highly multiplexed targeted
assays for comprehensive detection of pathogens from ocular specimens with high accuracy and speed. This
innovative approach leverages the advantages of the cutting-edge NanoString technology, which enables rapid
and simultaneous detection and quantification of hundreds of different DNA or RNA molecules while maintaining
excellent sensitivity per target. In preliminary studies, we demonstrated that our novel diagnostic approach can
detect the most important etiologies of sight-threatening infections in a highly multiplexed format, with high
sensitivity and specificity, and in a timely manner, reducing the time from sample to answer from days to 12
hours. With proof-of-principle established and analytical validations thoroughly performed for an initial panel able
to simultaneously detect 48 targets in a single reaction, we are now aiming to 1) further develop, expand, and
validate our panel with the goal of covering additional pathogens of relevance in keratitis with broader
geographical coverage and applicability, and 2) lay the groundwork necessary to translate this technology into
practice and facilitate its clinical implementation by performing extensive clinical validations using our existing
large biorepositories of specimens collected from patients presenting with infectious keratitis, uveitis and
endophthalmitis, and additional samples that will continue to be collected in the first years of the project. This
proposal will result in a technically novel and clinically useful diagnostic approach that will advance the diagnosis
of infections associated with great ocular morbidity globally, using an assay that can detect ~95% of the etiologies
of sight-threatening infections in only 12 hours, and with high accuracy, including difficult to culture and potentially
unculturable pathogens, making a single-reaction diagnostic test comprehensive at an unprecedented level. This
is expected to transform ocular infection treatment by supporting prompt initiation of therapy with an effective
drug at early stages of the infection, helping to save vision and promoting antimicrobial de-escalation to reduce
the overuse of empirical therapies and limit the spread of antimicrobial resistance.